AIA expands cancer benefit reach
AIA is offering its cancer treatment benefit as an optional addition to more of its policies.
Monday, August 28th 2017, 6:00AM
The benefit, which funds Medsafe-approved medicines not funded by Pharmac, had previously only been available as an add-on to AIA’s Real Trauma policies.
This has now been expanded to include Real life and total permanent disability policies.
“AIA New Zealand was the first to see a gap in the market for the Cancer Treatment Benefit, which we launched in March this year. Sales to date have been very encouraging,” David Savidan, AIA New Zealand’s head of marketing and product, said.
“Detecting cancer early, and getting access to the new generation of proven immunotherapy medicines, can greatly improve a person’s chances of surviving cancer.”
A course of one of the new generation of immunotherapy drugs such as Yervoy (for previously-treated or newly-diagnosed advanced melanoma cases) or the advanced prostate cancer drug Provenge, can cost between tens to hundreds of thousands of dollars per patient.
“AIA New Zealand’s cancer treatment benefit gives immediate access to specialists and diagnostic tools, as well as the leading medicines, whether they are publicly-funded or not,” Savidan said.
The benefit provides cover for specialist visits and diagnostic tests for the diagnosis of cancer. If cancer is present, it provides access to both Pharmac and non-Pharmac treatments and the latest cancer immunotherapy medicines, up to $500,000 per year.
| « Newpark considers being a licensed dealer group | Mixed reviews from advisers on FMA regulation » |
Special Offers
Comments from our readers
No comments yet
Sign In to add your comment
|
|
Printable version |
|
Email to a friend |
